Fluvastatin
( DrugBank: Fluvastatin / KEGG DRUG: Fluvastatin sodium, Fluvastatin )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 48 | Primary antiphospholipid syndrome | 1 |
| 79 | Homozygous familial hypercholesterolemia | 2 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 218 | Alport syndrome | 1 |
| 222 | Primary nephrotic syndrome | 1 |
48. Primary antiphospholipid syndrome
Clinical trials : 96 / Drugs : 112 - (DrugBank : 22) / Drug target genes : 20 - Drug target pathways : 138
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
79. Homozygous familial hypercholesterolemia
Clinical trials : 525 / Drugs : 330 - (DrugBank : 49) / Drug target genes : 20 - Drug target pathways : 59
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
218. Alport syndrome
Clinical trials : 47 / Drugs : 49 - (DrugBank : 23) / Drug target genes : 8 - Drug target pathways : 46
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
222. Primary nephrotic syndrome
Clinical trials : 576 / Drugs : 519 - (DrugBank : 130) / Drug target genes : 108 - Drug target pathways : 219
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|